Anuh Pharma Receives WHO Prequalification for Amodiaquine HCl USP

Anuh Pharma Ltd. has received World Health Organization (WHO) Prequalification (WHO PQ) approval for its Amodiaquine Hydrochloride USP (Amodiaquine HCl USP) active pharmaceutical ingredient (API). This approval allows the company to supply the anti-malarial API to international markets, including WHO-procured and donor-funded programs. Amodiaquine Hydrochloride is an essential medicine used in combination therapies for treating uncomplicated Plasmodium falciparum malaria. This prequalification strengthens Anuh Pharma's position as a preferred API supplier for global anti-malarial initiatives.